You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 10,208,355

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,208,355

Title:	Method of treatment for glioblastoma by administering a VEGF antagonist
Abstract:	The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
Inventor(s):	Bais; Carlos (South San Francisco, CA), Bourgon; Richard (South San Francisco, CA), Sandmann; Thomas (South San Francisco, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	15/346,164
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,208,355
Patent Claims:	1. A method of treating a patient having a glioblastoma, the method comprising administering a VEGF antagonist to the patient, wherein the patient has a decrease in the expression level of at least one gene selected from the group consisting of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the at least one gene, and wherein the reference level is the median level of expression of the at least one gene in a population of patients having a glioblastoma. 2. The method of claim 1, wherein the administered VEGF antagonist is an anti-VEGF antibody. 3. The method of claim 2, wherein the administered anti-VEGF antibody is bevacizumab. 4. The method of claim 2, wherein the administered anti-VEGF antibody comprises a VH and a VL, wherein said VH has an amino acid sequence of SEQ ID NO: 2 and said VL has an amino acid sequence of SEQ ID NO: 1. 5. The method of claim 1, further comprising administering (i) an agent selected from the group consisting of an anti-neoplastic agent, a chemotherapeutic agent, a growth inhibitory agent, and a cytotoxic agent, (ii) radiotherapy, or (iii) a combination thereof. 6. The method of claim 5, wherein the administered chemotherapeutic agent is TMZ. 7. The method of claim 1, wherein the patient has a glioblastoma of the non-proneural type. 8. The method of claim 1, wherein the patient has a decrease in the expression level of at least two genes selected from the group consisting of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the at least two genes. 9. The method of claim 1, wherein the patient has a decrease in the expression level of at least three genes selected from the group consisting of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the at least three genes. 10. The method of claim 1, wherein the patient has a decrease in the expression level of at least four genes selected from the group consisting of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the at least four genes. 11. The method of claim 1, wherein the patient has a decrease in the expression level of at least five genes selected from the group consisting of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the at least five genes. 12. The method of claim 1, wherein the patient has a decrease in the expression level of at least six genes selected from the group consisting of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the at least six genes. 13. The method of claim 1, wherein the patient has a decrease in the expression level of AXL, BCL2L1, CD36, ETS1, ICAM2, IL17A, IRS2, PDGFRB, RPL13A, TGFB1, TNFRSF4, TNFSF4, and ZBTB16 relative to a reference expression level of the genes. 14. The method of claim 1, wherein the treatment results in an increase in overall survival of the patient.

Details for Patent 10,208,355

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2039-03-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.